ITI-007: Phase III started

Intra-Cellular began the double-blind, placebo-controlled, U.S. Phase III ITI-007-301 trial to evaluate 40 and 60 mg oral ITI-007 once daily for 28 days in about 440 patients with an acutely exacerbat...